Assenagon Asset Management S.A. Sells 143,378 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Assenagon Asset Management S.A. lowered its position in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 9.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,334,315 shares of the company's stock after selling 143,378 shares during the quarter. Assenagon Asset Management S.A. owned about 2.70% of Cryoport worth $10,381,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in CYRX. Dynamic Technology Lab Private Ltd acquired a new stake in Cryoport in the third quarter worth $82,000. Hsbc Holdings PLC acquired a new stake in shares of Cryoport in the 2nd quarter worth about $92,000. Intech Investment Management LLC bought a new stake in Cryoport in the 3rd quarter valued at about $105,000. The Manufacturers Life Insurance Company boosted its stake in Cryoport by 9.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company's stock valued at $122,000 after purchasing an additional 1,534 shares during the period. Finally, NRI Wealth Management LC bought a new position in Cryoport in the 4th quarter worth about $149,000. 92.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on CYRX shares. Guggenheim began coverage on Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price on the stock. UBS Group lifted their price objective on shares of Cryoport from $7.00 to $9.00 and gave the company a "neutral" rating in a research note on Friday, October 18th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Cryoport in a research report on Friday. Finally, Roth Mkm reduced their price target on shares of Cryoport from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $12.29.

Insider Buying and Selling at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of the business's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the transaction, the director now directly owns 59,497 shares in the company, valued at $443,847.62. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jerrell Shelton sold 50,000 shares of the firm's stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the sale, the chief executive officer now owns 731,897 shares of the company's stock, valued at $4,764,649.47. This represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,869 shares of company stock valued at $735,673 in the last 90 days. 10.10% of the stock is currently owned by insiders.

Cryoport Stock Performance

CYRX traded up $0.01 during trading on Friday, hitting $7.50. The stock had a trading volume of 217,091 shares, compared to its average volume of 234,734. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The company has a 50 day simple moving average of $7.68 and a 200-day simple moving average of $7.86. Cryoport, Inc. has a 12 month low of $5.32 and a 12 month high of $20.10.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.